Literature DB >> 9202872

Quinine-induced hemolytic uremic syndrome.

S P McDonald1, E M Shanahan, A C Thomas, D J Roxby, D Beroukas, J A Barbara.   

Abstract

Although quinine use is very common, hemolytic uremic syndrome (HUS) following exposure to quinine is only a recently reported phenomenon, with the first description published in 1991. Previous reports have concentrated on the nature of the hematological process and in particular characterization of the quinine-induced antibodies involved. We present a case of HUS with a clear temporal and immunological relationship to quinine which demonstrates the pathognomonic renal features of HUS. An indirect antiglobulin test with the patient's serum agglutinated red blood cells only in the presence of quinine. Renal biopsy features included glomerular and arteriolar endothelial swelling, capillary loop thrombi, mesangiolysis, segmental sclerosis and segmental ischemia. Early empiric treatment with plasma exchange and corticosteroids was instituted and this resulted in recovery of renal function to normal.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9202872

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  4 in total

Review 1.  Drug-induced thrombotic microangiopathy: incidence, prevention and management.

Authors:  R Pisoni; P Ruggenenti; G Remuzzi
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 2.  Nocturnal leg cramps in older people.

Authors:  J V Butler; E C Mulkerrin; S T O'Keeffe
Journal:  Postgrad Med J       Date:  2002-10       Impact factor: 2.401

3.  Renal-limited thrombotic microangiopathy and acute interstitial nephritis with a single dose of quinine.

Authors:  Jobert Anjelo; Nitesh Rao; Vinoi G David; Sophia Otto; Graeme Russ
Journal:  Clin Kidney J       Date:  2014-05-07

4.  Chronic ingestion of high dosed Phikud Navakot extraction induces mesangiolysis in rats with alteration of AQP1 and Hsp60 expressions.

Authors:  Kanchana Kengkoom; Sumate Ampawong
Journal:  Biomed Res Int       Date:  2015-03-01       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.